Newlink Genetics reported $-7550000 in Operating Profit for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Agenus AGEN:US USD -41645000 2.92M
Bristol Myers Squibb BMY:US USD 2.47B 117M
Capricor Therapeutics CAPR:US USD -6478000 844K
Celldex Therapeutics CLDX:US USD -27696000 8.7M
Eli Lilly And LLY:US USD 1.68B 466.4M
Idera Pharmaceuticals IDRA:US USD -9327000 3.96M
Intrexon XON:US USD -7614000 16.55M
Merk MRK:US USD 3.99B 939M
Nektar Therapeutics NKTR:US USD -54301000 98.54M
Newlink Genetics NLNK:US USD -7550000 374K
Pfizer PFE:US USD 9.41B 2.69B
Prothena PRTA:US USD -50332000 7.12M
Sarepta Therapeutics SRPT:US USD -256796000 45.66M
Vascular Biogenics VBLT:US USD -9275000 339K
YTE INCY:US USD 138.38M 116.06M